Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INJECT: Intra-tumoral injections in metastatic urological cancers
NCT03071328Phase 1Completed
- Sponsor
- Duke University
- Start
- Jan 2018
- Primary completion
- Mar 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of Isovue 250 in metastatic castration-resistant prostate cancer (mCRPC), urothelial carcinoma (UC) and metastatic renal cell carcinoma (mRCC) (4 arms), sponsored by Duke University. Primary endpoints: Presence of iodinated contrast enhancement within the metastasis on post-injection CT at Day 1 and Percentage of iodinated contrast enhancement within the metastasis on post-injection CT at Day 1. Started Jan 2018; status: completed.
02
Drugs
Isovue 250
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)urothelial carcinoma (UC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03071328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071328.